Analysts Forecast 11% Growth Potential for JMEE Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 25 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The JPMorgan Market Expansion Enhanced Equity ETF (JMEE) has an implied analyst target price of $69.95 per unit, indicating a potential upside of 11.38% from its current trading price of $62.80.
Notable Holdings: Key underlying holdings with significant upside include Corcept Therapeutics Inc (CORT), Quanex Building Products Corp (NX), and Marathon Digital Holdings Inc (MARA), with expected increases of 91.24%, 64.66%, and 44.07% respectively.
Analyst Target Justification: Questions arise regarding whether analysts' target prices are justified or overly optimistic, considering recent developments in the companies and their industries.
Investor Research Needed: Investors are encouraged to conduct further research to assess the validity of these targets and the potential for future price adjustments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 73.330
Low
50.00
Averages
91.00
High
121.00
Current: 73.330
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Data Reveals Korlym's Potential in Diabetes Treatment
- Clinical Trial Results: At the ADA conference, the CATALYST trial demonstrated that patients treated with Korlym achieved a 1.3% reduction in HbA1c and a 5.1 kg weight loss, indicating significant efficacy in difficult-to-control diabetes, which could reshape treatment strategies.
- High Prevalence Confirmation: The MOMENTUM trial revealed that 27.3% of patients with resistant hypertension had hypercortisolism, underscoring the importance of this condition in cardiometabolic diseases and potentially driving broader screening and treatment efforts.
- Synergistic Effects with GLP-1 Agonists: Among patients receiving GLP-1 receptor agonists, those treated with Korlym experienced a 1.7% reduction in HbA1c and a 6.1 kg weight loss, highlighting its synergistic potential with existing therapies, which may enhance patient outcomes.
- Strategic Implications: These findings not only provide a rationale for screening for hypercortisolism but may also encourage more physicians to consider Korlym as an adjunct therapy for diabetes management, ultimately improving patient quality of life.
See More
New Data Reveals Korlym's Potential in Diabetes Treatment
- Clinical Trial Results: At the ADA conference, the CATALYST trial demonstrated that patients treated with Korlym achieved a 1.3% reduction in HbA1c and a 5.1 kg weight loss, indicating significant efficacy in managing difficult-to-control type 2 diabetes, which may alter treatment strategies.
- High Prevalence Confirmation: The MOMENTUM trial found that 27.3% of patients with resistant hypertension had endogenous hypercortisolism, highlighting the commonality of this condition among diabetes patients and suggesting a need for enhanced screening and treatment.
- Synergistic Effects with GLP-1 Agonists: In the CATALYST trial, patients on GLP-1 receptor agonists showed a 1.7% HbA1c reduction and a 6.1 kg weight loss with Korlym treatment, demonstrating the potential synergistic effect of Korlym with existing therapies, which could enhance patient outcomes.
- Strategic Implications: These findings not only provide a basis for screening hypercortisolism but may also promote the use of Korlym in diabetes treatment, strengthening the company's market position in the endocrinology sector.
See More
Corcept Presents New Survival Data for Lifyorli
- Significant Survival Improvement: Corcept's presentation at ASCO 2026 revealed that patients treated with Lifyorli plus nab-paclitaxel experienced a 35% reduction in death risk (HR: 0.65) with a median survival of 16.0 months, compared to 11.9 months for nab-paclitaxel alone, highlighting the clinical importance of this combination therapy for platinum-resistant ovarian cancer.
- New FDA Approval Standard: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, with no biomarker selection required, marking a new standard in cancer treatment and expected to enhance patient treatment options.
- Broad Applicability: The ROSELLA trial demonstrated significant survival benefits across all prespecified subgroups, including patients with poor prognostic features, indicating Lifyorli's consistent efficacy across diverse patient populations and its potential to reshape treatment paradigms for platinum-resistant ovarian cancer.
- Good Clinical Tolerability: The combination of Lifyorli with nab-paclitaxel was well-tolerated, with adverse events comparable to those in the nab-paclitaxel monotherapy group; although some patients experienced neutropenia, the overall safety profile supports its promotion in clinical practice.
See More
Corcept Plans to Resubmit New Drug Application for Cushing's Syndrome
- FDA Review Progress: Corcept plans to resubmit its New Drug Application (NDA) for Relacorilant, aimed at treating Cushing's syndrome, in the coming weeks, with the FDA expected to provide a Prescription Drug User Fee Act (PDUFA) date six months post-submission, enhancing investor optimism.
- Stock Price Recovery: Following the announcement of the NDA resubmission, Corcept's shares (CORT) reached their highest levels in 2026, rising over 7% in Wednesday's morning session and extending a five-day winning streak, reflecting market confidence in the company's future prospects.
- Patient Impact: Patients with Cushing's syndrome often experience symptoms such as high blood pressure and obesity, and untreated hypercortisolism can be life-threatening, with cardiovascular complications being the leading cause of death, highlighting the potential market demand for Relacorilant.
- Market Sentiment Analysis: Despite the recent stock price increase, retail sentiment for CORT on Stocktwits remains bearish, indicating cautious market views on the company's future FDA review outcomes, particularly with the anticipated Class 2 review.
See More
Corcept Therapeutics Stock Rises 7% After UBS Upgrade to Buy
- Rating Upgrade: UBS Group upgraded Corcept Therapeutics from Neutral to Buy, resulting in a more than 7% stock increase on Wednesday, indicating market optimism regarding its future performance.
- Price Target Increase: UBS raised its price target from $44 to $72, implying nearly a 41% upside from Tuesday's close of $51.16, reflecting analysts' confidence in the company's growth potential.
- Revenue Expectations: Analysts anticipate that the approval of Lifyoril for ovarian cancer will generate $936 million in peak PROC revenue, while Korlym sales are projected to reach $897 million by 2030, 17% above consensus, showcasing the company's competitive position in the market.
- Market Performance: Corcept Therapeutics' stock has gained over 58% year-to-date, significantly outperforming the S&P 500's 8% increase, indicating strong performance in the biopharmaceutical sector and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Nvidia's Positive Outlook: Oppenheimer reiterates Nvidia as an outperform, projecting CY26 free cash flow to approach $200 billion, and if half is allocated for dividends, the yield could reach nearly 2.5%, which would bolster investor confidence and drive stock price appreciation.
- Apple's Strong Ecosystem: Daiwa raises Apple's price target from $310 to $325, emphasizing its vast ecosystem as a core strength, while acknowledging potential memory management challenges in 2H CY26, the long-term outlook remains favorable for this core holding.
- Positive Outlook for Housing Platform: UBS upgrades KE Holdings to buy from neutral, citing significant upside due to its agency business in tier 1 cities, particularly as the market recovery is led by the secondary market, positioning the company for strong performance.
- Wendy's Potential Privatization: Argus upgrades Wendy's to buy from neutral, driven by news of a potential move to take the restaurant chain private, with Trian Fund Management owning about 40% of the stock, indicating strong market confidence in this strategic shift.
See More
New Data Reveals Korlym's Potential in Diabetes Treatment
- Clinical Trial Results: At the ADA conference, the CATALYST trial demonstrated that patients treated with Korlym achieved a 1.3% reduction in HbA1c and a 5.1 kg weight loss, indicating significant efficacy in difficult-to-control diabetes, which could reshape treatment strategies.
- High Prevalence Confirmation: The MOMENTUM trial revealed that 27.3% of patients with resistant hypertension had hypercortisolism, underscoring the importance of this condition in cardiometabolic diseases and potentially driving broader screening and treatment efforts.
- Synergistic Effects with GLP-1 Agonists: Among patients receiving GLP-1 receptor agonists, those treated with Korlym experienced a 1.7% reduction in HbA1c and a 6.1 kg weight loss, highlighting its synergistic potential with existing therapies, which may enhance patient outcomes.
- Strategic Implications: These findings not only provide a rationale for screening for hypercortisolism but may also encourage more physicians to consider Korlym as an adjunct therapy for diabetes management, ultimately improving patient quality of life.
See More
New Data Reveals Korlym's Potential in Diabetes Treatment
- Clinical Trial Results: At the ADA conference, the CATALYST trial demonstrated that patients treated with Korlym achieved a 1.3% reduction in HbA1c and a 5.1 kg weight loss, indicating significant efficacy in managing difficult-to-control type 2 diabetes, which may alter treatment strategies.
- High Prevalence Confirmation: The MOMENTUM trial found that 27.3% of patients with resistant hypertension had endogenous hypercortisolism, highlighting the commonality of this condition among diabetes patients and suggesting a need for enhanced screening and treatment.
- Synergistic Effects with GLP-1 Agonists: In the CATALYST trial, patients on GLP-1 receptor agonists showed a 1.7% HbA1c reduction and a 6.1 kg weight loss with Korlym treatment, demonstrating the potential synergistic effect of Korlym with existing therapies, which could enhance patient outcomes.
- Strategic Implications: These findings not only provide a basis for screening hypercortisolism but may also promote the use of Korlym in diabetes treatment, strengthening the company's market position in the endocrinology sector.
See More
Corcept Presents New Survival Data for Lifyorli
- Significant Survival Improvement: Corcept's presentation at ASCO 2026 revealed that patients treated with Lifyorli plus nab-paclitaxel experienced a 35% reduction in death risk (HR: 0.65) with a median survival of 16.0 months, compared to 11.9 months for nab-paclitaxel alone, highlighting the clinical importance of this combination therapy for platinum-resistant ovarian cancer.
- New FDA Approval Standard: Lifyorli received FDA approval in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer, with no biomarker selection required, marking a new standard in cancer treatment and expected to enhance patient treatment options.
- Broad Applicability: The ROSELLA trial demonstrated significant survival benefits across all prespecified subgroups, including patients with poor prognostic features, indicating Lifyorli's consistent efficacy across diverse patient populations and its potential to reshape treatment paradigms for platinum-resistant ovarian cancer.
- Good Clinical Tolerability: The combination of Lifyorli with nab-paclitaxel was well-tolerated, with adverse events comparable to those in the nab-paclitaxel monotherapy group; although some patients experienced neutropenia, the overall safety profile supports its promotion in clinical practice.
See More
Corcept Plans to Resubmit New Drug Application for Cushing's Syndrome
- FDA Review Progress: Corcept plans to resubmit its New Drug Application (NDA) for Relacorilant, aimed at treating Cushing's syndrome, in the coming weeks, with the FDA expected to provide a Prescription Drug User Fee Act (PDUFA) date six months post-submission, enhancing investor optimism.
- Stock Price Recovery: Following the announcement of the NDA resubmission, Corcept's shares (CORT) reached their highest levels in 2026, rising over 7% in Wednesday's morning session and extending a five-day winning streak, reflecting market confidence in the company's future prospects.
- Patient Impact: Patients with Cushing's syndrome often experience symptoms such as high blood pressure and obesity, and untreated hypercortisolism can be life-threatening, with cardiovascular complications being the leading cause of death, highlighting the potential market demand for Relacorilant.
- Market Sentiment Analysis: Despite the recent stock price increase, retail sentiment for CORT on Stocktwits remains bearish, indicating cautious market views on the company's future FDA review outcomes, particularly with the anticipated Class 2 review.
See More
Corcept Therapeutics Stock Rises 7% After UBS Upgrade to Buy
- Rating Upgrade: UBS Group upgraded Corcept Therapeutics from Neutral to Buy, resulting in a more than 7% stock increase on Wednesday, indicating market optimism regarding its future performance.
- Price Target Increase: UBS raised its price target from $44 to $72, implying nearly a 41% upside from Tuesday's close of $51.16, reflecting analysts' confidence in the company's growth potential.
- Revenue Expectations: Analysts anticipate that the approval of Lifyoril for ovarian cancer will generate $936 million in peak PROC revenue, while Korlym sales are projected to reach $897 million by 2030, 17% above consensus, showcasing the company's competitive position in the market.
- Market Performance: Corcept Therapeutics' stock has gained over 58% year-to-date, significantly outperforming the S&P 500's 8% increase, indicating strong performance in the biopharmaceutical sector and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Nvidia's Positive Outlook: Oppenheimer reiterates Nvidia as an outperform, projecting CY26 free cash flow to approach $200 billion, and if half is allocated for dividends, the yield could reach nearly 2.5%, which would bolster investor confidence and drive stock price appreciation.
- Apple's Strong Ecosystem: Daiwa raises Apple's price target from $310 to $325, emphasizing its vast ecosystem as a core strength, while acknowledging potential memory management challenges in 2H CY26, the long-term outlook remains favorable for this core holding.
- Positive Outlook for Housing Platform: UBS upgrades KE Holdings to buy from neutral, citing significant upside due to its agency business in tier 1 cities, particularly as the market recovery is led by the secondary market, positioning the company for strong performance.
- Wendy's Potential Privatization: Argus upgrades Wendy's to buy from neutral, driven by news of a potential move to take the restaurant chain private, with Trian Fund Management owning about 40% of the stock, indicating strong market confidence in this strategic shift.
See More
